ReviewFrontiers in immunology2026
Cellular heterogeneity and multicellular mechanisms in the pathogenesis of late-life depression: insights from single-cell and spatial multi-omics.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Late-life depression (LLD) is a heterogeneous disorder characterised by affective symptoms, cognitive decline, vascular burden, frailty, treatment resistance, and an increased risk of neurodegenerative progression, yet bulk molecular approaches may obscure the cell-type-specific alterations underlying this clinical and biological heterogeneity. This narrative review synthesises single-cell, single-nucleus, spatial, and multi-omic evidence concerning neuronal, glial, vascular, and peripheral immune alterations relevant to LLD, while distinguishing direct findings from clinically defined or older-adult depression cohorts from evidence extrapolated from major depressive disorder, ageing, mild cognitive impairment, Alzheimer's disease, and experimental models. The strongest current evidence implicates selective excitatory and inhibitory neuronal subtypes and astrocytes in prefrontal affective-cognitive circuit dysfunction, whereas endothelial and neurovascular-unit abnormalities, microglial reprogramming, oligodendrocyte-lineage dysfunction, hippocampal plasticity deficits, and peripheral immune remodelling represent biologically plausible but less well-validated mechanisms. Ageing-related cellular alterations, blood-brain barrier disruption, endothelial-astrocyte dysregulation, neuroinflammation, impaired myelin maintenance, and hippocampal vulnerability may interact to contribute to affective, cognitive, vascular, and treatment-resistant phenotypes. However, direct single-cell and spatial multi-omics evidence from clinically defined LLD cohorts remains scarce, and peripheral immune signatures should be interpreted primarily as accessible systemic correlates rather than direct measures of brain pathology. Overall, current evidence supports a hypothesis-generating multicellular framework rather than validated LLD-specific mechanisms or therapeutic targets. Future studies integrating single-nucleus and spatial multi-omics with longitudinal clinical phenotyping, neuroimaging, peripheral immune profiling,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.